Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.55 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.55 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21856082 | 0.94 | EPHX1 (0.50) | GNAI3GNAO1GNAI1EPHX1GAA | |
| SCHEMBL951710 | 0.91 | GAA (0.50) | GNAI3GNAO1GNAI1EPHX1GAA | |
| SCHEMBL28246288 | 0.91 | GAA (0.50) | GNAI3GNAO1GNAI1EPHX1GAA | |
| SCHEMBL28229178 | 0.91 | GAA (0.50) | GNAI3GNAO1GNAI1EPHX1GAA | |
| SCHEMBL8851435 | 0.90 | EPHX1 (0.50) | GNAI3GNAO1GNAI1EPHX1GAA | |
| SCHEMBL30135801 | 0.89 | GAA (0.46) | GNAI3GNAO1GNAI1EPHX1GAA | |
| SCHEMBL4719490 | 0.88 | GAA (0.59) | EPHX1GAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL13387564 | 0.88 | GAA (0.59) | EPHX1GAAMAPK1HTTSMN1; SMN2 | |
| Bicarbonate SCHEMBL9827045 | 0.88 | GAA (0.48) | GNAI3GNAO1GNAI1EPHX1GAA | |
| SCHEMBL1827279 | 0.85 | EPHX1 (0.64) | EPHX1GAAMAPK1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101899058-A | Method for preparing thiazolopyrimidine compound and application thereof | FOURTH MILITARY MEDICAL UNIV | 2010-12-01 | — | — | CN | claimed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | claimed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | claimed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| EP-4431504-A1 | AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Shanghai Institute of Material Medica, Chinese Academy of Sciences (CN) | 2024-09-18 | — | — | EP | disclosed |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2022-12-22 | — | — | US | disclosed |
| EP-3947368-A1 | CDK2/5 DEGRADERS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3793552-A1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | The Scripps Research Institute (US) | 2021-03-24 | — | — | EP | disclosed |
| CN-103193773-B | Pyridyloxyindoles inhibitors of VEGF-R2 and their use for treating diseases | NOVARTIS AG | 2014-12-10 | — | — | CN | disclosed |
| CN-102307870-B | Pyridyloxyindoles inhibitors of VEGF-R2 and their use for treating diseases | NOVARTIS AG | 2014-06-18 | — | — | CN | disclosed |
| CN-101959882-B | Imidazole carbonyl compound | DAIICHI SANKYO CO LTD | 2013-09-11 | — | — | CN | disclosed |
| CN-101932577-B | Heteroaryl-substituted piperidines | BAYER HEALTHCARE AG | 2013-07-17 | — | — | CN | disclosed |
| CN-1882568-A | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | CN | disclosed |
| WO-2006028904-A9 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | disclosed |
| WO-2005019200-A2 | ARYL PIPERIDINE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
| EP-0467325-A2 | Carbostyril derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-01-22 | — | — | EP | disclosed |
| US-5082847-A | Antiarrhythmia | SYNTEX (U.S.A.) INC. (US) | 1992-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | GNAI3 508/4885GNAO1 568/4885GNAI1 872/4885 |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | GNAI3 1473/4885GNAO1 1989/4885GNAI1 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.